Author Archives: Cassidy Brady

Rapidly Translating Novel Vaccine Concepts into the Clinic

CRM197 is a nontoxic mutant of diphtheria toxin containing a single amino-acid substitution of glutamic acid for glycine. CRM197 is a well-characterized carrier protein used in a number of approved and highly successful conjugate vaccines including Pfizer’s Prevnar® pneumococcal vaccine, a multibillion-dollar franchise; HibTiter® (Haemophilus influenzae b) vaccine, and Novartis’ Menveo® meningococcal vaccine. Traditionally, CRM197 is produced by fermentation of a Corynebacterium diphtheriae C7 (β197) tox (–) strain, which secretes it into the culture supernatant. It is then recovered after…

Carrier Protein Outsourcing

    Vaccines represent a significant, increasing area of product development within the biopharmaceutical industry. The segment includes several blockbuster commercial products, nearly 300 vaccines currently in development, and many more candidates in various stages of research and preclinical development (1). The 2010 worldwide vaccine market was ~US$20 billion and is projected to approach $30 billion by 2015 (2). Conjugate vaccines sales currently exceed $7 billion and are expected to increase substantially. Conjugate vaccines (covalently linked polysaccharide and protein) have…

Expression of a Self-Assembling Antigen-Targeting Fusion Protein

    Figure 1: ()   The Pfēnex Expression Technology™ platform is a very powerful protein expression technology based on the microorganism, Pseudomonas fluorescens. The Pfenex platform can deliver a robust production strain with unprecedented speed and a success rate that transcends legacy production hosts. Traditional recombinant protein expression hosts such as E. coli, insect cells, and yeast tend to have high failure rates regarding their ability to produce high titers of soluble, full-length, active target protein. In addition, the…

Expression of a Fab Fragment in Pfēnex Expression Technology™

          The Pfēnex Expression Technology™ platform is a powerful protein Expression Technology based on the novel host Pseudomonas fluorescens. Legacy recombinant protein expression hosts such as E. coli and yeast tend to have high failure rates with regard to expression of soluble, active protein. In addition, the time required to identify the optimal expression strain in these systems is protracted, resulting in significant opportunity cost for drug developers. Leveraging the Pfēnex Expression Technology™ shortens development time…